News

Coal India is currently trading at Rs. 128.75, down by 1.75 points or 1.34% from its previous closing of Rs. 130.50 on the BSE.

The scrip opened at Rs. 130.50 and has touched a high and low of Rs. 130.55 and Rs. 128.15 respectively. So far 204086 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 234.00 on 17-Jul-2019 and a 52 week low of Rs. 119.25 on 26-Mar-2020.

Last one week high and low of the scrip stood at Rs. 135.25 and Rs. 128.10 respectively. The current market cap of the company is Rs. 79406.75 crore.

The promoters holding in the company stood at 66.13%, while Institutions and Non-Institutions held 30.07% and 3.73% respectively.

Coal India’s dues from state- owned power generation companies have risen to Rs 22,000 crore amid muted demand and high production. The mining behemoth is also not in a position to regulate supplies to the power companies as demand has remained subdued over the last few months.

Coal India is the world’s largest coal mining company. It also produces non-coking coal and coking coal of various grades for diverse applications.

KPIT Technologies is currently trading at Rs. 66.25, up by 1.65 points or 2.55% from its previous closing of Rs. 64.60 on the BSE.

The scrip opened at Rs. 66.40 and has touched a high and low of Rs. 67.70 and Rs. 64.40 respectively. So far 23208 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 111.10 on 16-Jan-2020 and a 52 week low of Rs. 34.45 on 26-Mar-2020.

Last one week high and low of the scrip stood at Rs. 67.70 and Rs. 58.50 respectively. The current market cap of the company is Rs. 1812.09 crore.

The promoters holding in the company stood at 41.81%, while Institutions and Non-Institutions held 35.56% and 22.64% respectively.

KPIT Technologies has declared its contribution towards community through an innovation of portable, versatile ventilators to equip the medical fraternity with affordable medical devices for the treatment of COVID-19. The ventilators are designed to serve the entire need of support spectrum from ambulances to ICUs (intensive care units) as well as at-home-care; and are compatible with both AMBU (Artificial Manual Breathing Unit) bags and compressors.

These ventilators have been certified by NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited laboratories and validated as versatile, safe and robust by doctors.

KPIT is a global technology company with software solutions that will help mobility leapfrog towards an autonomous, clean, smart and connected future.

Phillips Carbon Black is currently trading at Rs. 107.10, up by 0.90 points or 0.85% from its previous closing of Rs. 106.20 on the BSE.

The scrip opened at Rs. 106.90 and has touched a high and low of Rs. 108.40 and Rs. 103.55 respectively. So far 81609 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 147.40 on 22-Jan-2020 and a 52 week low of Rs. 54.20 on 24-Mar-2020.

Last one week high and low of the scrip stood at Rs. 119.00 and Rs. 103.55 respectively. The current market cap of the company is Rs. 1834.54 crore.

The promoters holding in the company stood at 53.56%, while Institutions and Non-Institutions held 14.66% and 31.78% respectively.

Phillips Carbon Black (PCBL) has finalised a site near Chennai in Tamil Nadu to set up its Rs 600 crore greenfield plant, and all its expansion programmes are on track. The company has also commissioned its second research and development (R&D) centre in Belgium in June amid the coronavirus pandemic. The project awaits a few final approvals, and the construction is expected to begin in the second half of the current fiscal. The company had been discussing with the state governments of Tamil Nadu, Andhra Pradesh and Telangana for setting up the plant.

Phillips Carbon Black is the largest manufacturer and supplier of carbon black in the country catering to the needs of elastomer, plastic, paints and ink manufacturing industries.

Hexaware Technologies is currently trading at Rs. 353.20, up by 6.95 points or 2.01% from its previous closing of Rs. 346.25 on the BSE.

The scrip opened at Rs. 346.00 and has touched a high and low of Rs. 358.40 and Rs. 345.90 respectively. So far 50761 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 398.95 on 09-Aug-2019 and a 52 week low of Rs. 201.70 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 358.40 and Rs. 335.40 respectively. The current market cap of the company is Rs. 10492.18 crore.

The promoters holding in the company stood at 62.44%, while Institutions and Non-Institutions held 29.68% and 7.88% respectively.

Hexaware Technologies has launched of COCO, the Unified Teams Bot built for Microsoft Teams, on Microsoft AppSource, an online cloud marketplace providing tailored line-of-business solutions. With the unprecedented and extraordinary times in the backdrop, the company is now more focused than ever on delivering touchless, immersive experiences, and automation-led cost savings for customers who have moved to remote working arrangements. The company also recognizes the market need to build and foster cloud resilience to ensure preparedness and optimized responses in the event of recurring contingencies.

Hexaware, a Microsoft Gold Partner, delivers differentiated offerings across the Microsoft cloud ecosystem, and designs solutions and strategies that help boost teamwork, and improve employee productivity and enhance employee experience. COCO, Hexaware’s omnichannel chat bot, is a step in the direction of making work easier, safer and sustainable for customers as they gradually bring employees back to the workplace amidst and post the COVID-19 pandemic.

COCO seamlessly integrates with existing disparate backend IT systems and platforms like ERP, CRM, Service Desk or any other enterprise systems. Employees can use COCO, straight from their Microsoft Teams app on desktop or mobile devices, to access information and undertake transactions with key business functions through a unified, simple, and conversational interface. COCO is built on Microsoft Azure Cognitive Services including LUIS to enable intuitive conversations.

Hexaware Technologies is a global provider of disruptive IT & IT-enabled services, complex technology solutions and automation-led Business Process services.

Deccan Health Care is currently trading at Rs. 37.00, up by 0.20 points or 0.54% from its previous closing of Rs. 36.80 on the BSE.
The scrip opened at Rs. 36.95 and has touched a high and low of Rs. 37.10 and Rs. 35.80 respectively. So far 32400 shares were traded on the counter.
The BSE group ‘M’ stock of face value Rs. 10 has touched a 52 week high of Rs. 94.00 on 09-Oct-2019 and a 52 week low of Rs. 19.05 on 15-Apr-2020.
Last one week high and low of the scrip stood at Rs. 37.80 and Rs. 35.50 respectively. The current market cap of the company is Rs. 58.14 crore.
The promoters holding in the company stood at 45.61%, while Non-Institutions held 54.39% stake in the company.
Deccan Health Care has received HealthCare Excellence award 2020 for Innovative Online Wellness Store – BeYoung Store. CIMS Medica held their HealthCare Excellence Award 2020 Ceremony, Virtually due to ongoing pandemic all over the world on July 05, 2020.
Deccan Health Care is engaged in developing, manufacturing and marketing a broad range of healthcare products including nutraceutical, cosmeceutical and ayurveda products.

Alembic Pharmaceuticals is currently trading at Rs. 950.00, up by 6.10 points or 0.65% from its previous closing of Rs. 943.90 on the BSE.
The scrip opened at Rs. 945.65 and has touched a high and low of Rs. 969.00 and Rs. 941.80 respectively. So far 13556 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 984.00 on 22-Jun-2020 and a 52 week low of Rs. 436.10 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 969.85 and Rs. 905.00 respectively. The current market cap of the company is Rs. 17999.50 crore.
The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 14.40% and 12.63% respectively.
Alembic Pharmaceuticals is looking at enhancing profitability of its domestic business and expects it to grow in double digits in the current financial year (FY21) with focus on high-margin products. The company aims to grow its presence in the specialty and chronic therapy segments. The drug firm has already started witnessing an uptick in domestic business with new product strategy in place. Strong brand recall, an efficient sales force, a growing network of supportive doctors and timely product launches are the key catalysts for this business.
In 2019-20, the company’s revenues from domestic business stood at Rs 1,425 crore, a growth of 3 per cent over Rs 1,382 crore in 2018-19, and accounted for 31 per cent of the company’s overall revenues that stood at Rs 4,606 crore. The company’s international generics business, on the other hand, accounted for 54 per cent of its overall revenues in 2019-20. The segment saw a revenue growth of 39 per cent to Rs 2,473 crore in 2019-20.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Avenue Supermarts is currently trading at Rs. 2189.00, down by 43.45 points or 1.95% from its previous closing of Rs. 2232.45 on the BSE.
The scrip opened at Rs. 2230.00 and has touched a high and low of Rs. 2230.00 and Rs. 2180.50 respectively. So far 14643 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 2559.00 on 13-Feb-2020 and a 52 week low of Rs. 1370.05 on 22-Jul-2019.
Last one week high and low of the scrip stood at Rs. 2384.95 and Rs. 2180.50 respectively. The current market cap of the company is Rs. 142254.56 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 16.40% and 8.61% respectively.
The company has reported 85.22% fall in its net profit of Rs 49.56 crore for first quarter ended June 30, 2020 as against Rs 335.31 crore for the same quarter in the previous year. Total income of the company decreased by 32.94% at Rs 3884.57 crore for Q1FY21 as compared Rs 5792.47 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported 87.59% fall in its net profit attributable to equity holders of the parent at Rs 40.09 crore for the quarter under review as against Rs 323.09 crore for the same quarter in the previous year. Total income of the company decreased by 32.47% at Rs 3933.78 crore for Q1FY21 as compared Rs 5825.51 crore for the corresponding quarter previous year.

Balaji Telefilms is currently trading at Rs. 76.00, down by 2.25 points or 2.88% from its previous closing of Rs. 78.25 on the BSE.

The scrip opened at Rs. 79.00 and has touched a high and low of Rs. 79.00 and Rs. 75.50 respectively. So far 2243 shares were traded on the counter.

The BSE group ‘B’ stock of face value Rs. 2 has touched a 52 week high of Rs. 83.00 on 19-Jul-2020 and a 52 week low of Rs. 28.00 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 81.00 and Rs. 75.20 respectively. The current market cap of the company is Rs. 765.56 crore.

The promoters holding in the company stood at 34.33%, while Institutions and Non-Institutions held 19.71% and 45.95% respectively.

Balaji Telefilms has halted shoot of all their television shows, as one of their actor has tested positive for COVID-19. The company is doing all that is required to ensure the safety of cast, production crew and employees.

Balaji Telefilms is India’s leading integrated media conglomerate with market leadership in the motion picture and television content industries, among other entertainment-led businesses.

Biocon is currently trading at Rs. 423.85, up by 9.25 points or 2.23% from its previous closing of Rs. 414.60 on the BSE.

The scrip opened at Rs. 423.00 and has touched a high and low of Rs. 428.60 and Rs. 417.50 respectively. So far 144958 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 455.00 on 13-Jul-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.

Last one week high and low of the scrip stood at Rs. 455.00 and Rs. 396.00 respectively. The current market cap of the company is Rs. 49752.00 crore.

The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 23.11% and 16.21% respectively.

Biocon has received the Drugs Controller General of India’s (DCGI) approval to market Itolizumab (ALZUMAb) Injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19.

Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications. Biocon has repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in India in 2013 as ALZUMAb for treating chronic plaque psoriasis, for the treatment of CRS in moderate to severe ARDS patients due to COVID-19. Itolizumab will be manufactured and formulated as an intravenous injection at Biocon’s bio-manufacturing facility at Biocon Park, Bengaluru.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient’s worldwide.

Coromandel International is currently trading at Rs. 754.30, up by 2.85 points or 0.38% from its previous closing of Rs. 751.45 on the BSE.

The scrip opened at Rs. 755.00 and has touched a high and low of Rs. 755.05 and Rs. 746.70 respectively. So far 1404 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 778.35 on 08-Jul-2020 and a 52 week low of Rs. 336.50 on 16-Aug-2019.

Last one week high and low of the scrip stood at Rs. 778.35 and Rs. 741.00 respectively. The current market cap of the company is Rs. 22028.26 crore.

The promoters holding in the company stood at 61.63%, while Institutions and Non-Institutions held 23.21% and 15.16% respectively.

Coromandel International has redeemed Commercial Paper (CP) amounting of Rs 200 crore on July 13, 2020. Earlier, the company had issued 4000 units of commercial paper amounting Rs 200 crore on April 15, 2020.

Coromandel International is engaged in the manufacturing of fertilizers, plant protection chemicals and speciality nutrients.